Safety and Efficacy of Carotid Artery Stenting with the CGuard Double-layer Stent in Acute Ischemic Stroke

Tomas Klail1 · Christoph Kurmann1,3 · Johannes Kaesmacher1 · Adnan Mujanovic1 · Eike I. Piechowiak1 · Tomas Dobrocky1 · Sara Pilgram-Pastor1 · Adrian Scutelnici2 · Mirjam R. Heldner2 · Jan Gralla1 · Pasquale Mordasini1

Received: 18 May 2022 / Accepted: 30 July 2022 / Published online: 7 September 2022 © The Author(s) 2022

Abstract
Background  Double-layer stents show promising results in preventing periinterventional and postinterventional embolic events in elective settings of carotid artery stenting (CAS). We report a single-center experience with the CGuard stent in the treatment of acute ischemic stroke (AIS) due to symptomatic internal carotid artery (ICA) stenosis or occlusion with or without intracranial occlusion.

Methods  We retrospectively analyzed all patients who received a CGuard stent in the setting of AIS at our institution. Neuroimaging and clinical data were analyzed with the following primary endpoints: technical feasibility, acute and delayed stent occlusion or thrombosis, distal embolism, symptomatic intracranial hemorrhage (sICH) and functional outcome at 3 months.

Results  In 33 patients, stenting with the CGuard was performed. Stent deployment was successful in all patients (28 with tandem occlusions, 5 with isolated ICA occlusion). Transient acute in-stent thrombus formation occurred in three patients (9%) without early stent occlusion. Delayed, asymptomatic stent occlusion was seen in 1 patient (3%) after 49 days. Asymptomatic periinterventional distal emboli occurred in 2 patients (6%), 1 patient experienced a transient ischemic attack 79 days after the procedure and 1 patient (3%) developed sICH. Favorable clinical outcome (mRS 0–2) at 3 months was achieved in 12 patients (36%) and the mortality rate was 24%.

Conclusion  The CGuard use in emergencies was technically feasible, the safety has to be confirmed by further multicentric studies.

Keywords  Emergency · Recanalization · Tandem occlusion · Stenosis · Embolism

Introduction

Several studies have shown that carotid artery stenting (CAS) is a valid treatment option for internal carotid artery (ICA) stenosis [1–3]; however, a potential complication of CAS is periprocedural or delayed embolism either due to dislodgement of plaque debris during periprocedural manipulation or, especially in open-cell stents, due to protrusion of plaque or thrombotic material through the struts of the expanded stent [4, 5].

To address this issue, a new generation of double-layered stents has been introduced into clinical practice. Studies have demonstrated a reduction of procedure-related embolizations in the elective setting in patients on standard double antiplatelet therapy [6, 7]. These stent features would also be useful in acute stroke treatment since most plaques are vulnerable to adherent thrombus and often
prone to embolization. This could be prevented by containing the thrombus between the arterial wall and the outer layer of the stent.

However, the debate around open versus closed cell stents has not yet been settled since many metal braided double-layer stents seem to show a tendency to in-stent thrombus formation or decreased vessel compliance in the acute setting [8–11]. The CGuard stent (InspireMD Inc., Tel Aviv, Israel) represents a new generation of carotid double-layered stents [12] comprised of an inner open-cell laser-cut nitinol stent and an outer closed-cell polyethylene terephthalate mesh layer, thus reducing the amount of thrombogenic material in the stent [13].

We therefore hypothesized that the CGuard stent would be suitable for application in emergency CAS and we present the first analytic overview of its use in acute extracranial ICA stenting.

**Methodology**

**Patient Selection**

All patients with acute symptomatic extracranial ICA occlusion or high-grade stenosis with or without intracranial vessel occlusion (tandem occlusion), who were treated with the CGuard stent at the University Hospital of Bern, Switzerland, were collected prospectively between December 2018 and November 2021. The study was approved by the local ethics committee (amendment access number: 231/2014).

Patients underwent endovascular intervention immediately after computer tomography (CT) or magnetic resonance imaging (MRI) if (1) diagnosis of ischemic stroke was established on imaging by a neuroradiologist, (2) intracranial hemorrhage was excluded on CT or MRI, (3) symptom duration was not longer than 24 h, (4) no further clinical conditions contraindicated the procedure [14] and (5) occlusion or severe stenosis of the cervical ICA (with or without an intracranial occlusion) was demonstrated by initial or peri-interventional imaging. When indicated, intravascular thrombolysis (IVT) was administered prior to endovascular therapy.

**Device**

The CGuard stent is a double-layered stent consisting of an inner open-cell laser-cut nitinol stent and an outer closed-cell polyethylene terephthalate mesh layer with filament diameters of 92–125 µm and 25 µm, respectively. It is a self-expanding system delivered through a 6 French access catheter and is available in sizes of 6–10 mm in diameter and 20–60 mm in length [15]. The pore size of the inner layer when fully expanded is 150–180 µm [6].

**Endovascular Procedure**

The general approach to treating tandem occlusions at our institution has been described previously [16, 17]. Briefly, all patients underwent the endovascular procedures under general anesthesia. After puncture of the common femoral artery, an 8 or 9 French sheath was introduced. Selective digital subtraction angiography (DSA) of the three non-occluded cervical vessels was routinely performed on a biplane high-resolution angiographic system (Artis Icono and Artis Q; Siemens, Erlangen, Germany) to assess cross flow and collaterals, followed by angiography of the occluded vessel. Based on clinical data and angiographic morphology, atheromatous occlusions were distinguished from ICA dissections.

A retrograde approach was chosen for all patients with tandem occlusions (treatment of the extracranial ICA occlusion or stenosis after intracranial recanalization) [3, 18]. After placement of a guiding catheter (8 French Guider Softtip, Boston Scientific, Marlborough, MA, USA; 9 French Merci balloon-guide catheter, Concentric Medical, Mountain View, CA, USA) a 0.021” microcatheter (Prowler Select Plus, Codman & Shurtleff Inc., Raynham, MA, USA; Phenom 21, Medtronic, Dublin, Ireland) was navigated through the stenosis over a 0.014” microwire (Traxess, Microvention, Aliso Viejo, CA, USA) under proximal balloon occlusion and flow arrest. Only when intracranial access was not possible due to difficult vessel anatomy or high-grade stenosis, was balloon angioplasty of the ICA stenosis performed first. Once the microcatheter position distally to the occlusion or stenosis had been confirmed by a contrast injection, an intermediate 5 or 6 French catheter (5max ACE, Penumbra, Alameda, CA, USA; Vasco +35Aspi, Balt Extrusion, Montmorency, France; Sophia 5/6 French, Microvention, React 68/71, Medtronic) was advanced over the microcatheter into the distal ICA. The intracranial thrombus was passed with a microcatheter over the microwire and mechanical thrombectomy (MT) was performed using a stent retriever device with distal aspiration. Successful recanalization was defined as a modified thrombectomy in cerebral infarction (mTICI) of 2b or 3.

Before performing cervical stenting or PTA, a filter protection device (FilterWire EZ, Boston Scientific) was placed distal to the ICA occlusion to protect against distal embolization before deflation of the balloon-guided catheter and implantation of the CGuard stent at the stenotic site of the ICA. The final decision on whether to stent was at the discretion of the treating physicians. Predilatation and post-dilatation was performed using balloon angioplasty (Aviator Plus PTA Dilatation Catheter, Cardinal Health, Dublin, OH, USA). DSA was performed at the end of the stent implantation process to check for acute in-stent thrombosis, distal embolism or other complications. Standard an-
Platelet therapy consisted of intravenous administration of 250–500 mg aspirin after intracranial recanalization, prior to stenting. Control imaging was performed within 24 h to exclude intracranial hemorrhage and assess infarct evolution. If no intracranial hemorrhage was detected, dual antiplatelet therapy (DAPT) with additional clopidogrel 75 mg was initiated and continued for 3–6 months. All imaging data were analyzed by an interventional neuroradiologist.

**Outcome Evaluation**

The National Institutes of Health Stroke Scale (NIHSS) was assessed by a neurologist on admission and at discharge. Following internal guidelines, CT or MRI within 24 h after the intervention was used to assess intracranial bleeding and infarct evolution. Symptomatic intracranial hemorrhage (sICH) was defined as hemorrhage associated with a decline of ≥ 4 points in the NIHSS [19]. Stent patency was assessed using ultrasound or CT or MR angiography. Routine clinical follow-up was performed at 3 months by an independent neurologist to evaluate patients’ recovery. The modified Rankin Scale (mRS) at 3 months was used as the indicator of clinical outcome.

**Fig. 1** Patient with an internal carotid artery (ICA) stenosis on the left side and a concurrent distal tandem occlusion. 

- **a** Diagnostic angiogram showing an occlusion in the M1 segment (smaller arrow) of the middle cerebral artery (MCA) and a high-grade stenosis at the carotid bifurcation (larger arrow).
- **b** Control angiogram after mechanical thrombectomy shows reperfusion of the MCA.
- **c** Control angiogram after CGuard stent placement shows normal caliber of the ICA.

**Statistical Analysis**

All characteristics (baseline, procedure, outcome) were analyzed using descriptive statistics. Normally distributed continuous variables are presented as mean ± standard deviation (SD), non-normally distributed continuous variables as median with interquartile range (IQR). Categorical variables are expressed as absolute numbers and percentages or as median with IQR. Normality was tested using graphical distribution and the Shapiro-Wilk test. Missing values were not imputed. All calculations were performed using R (R Core Team, Version 4.0.0) [20].

**Results**

**Patient Population**

Of the 33 patients, 25 (76%) were male, mean age was 73 years (IQR 63–80 years) and the median NIHSS score on admission was 13 (IQR 11–20). Of the patients 11 (33%) were under antiplatelet or anticoagulation therapy at the time of admission: 9 on aspirin monotherapy, 1 on clopidogrel and 1 on edoxaban.
The median Alberta Stroke Programme Early CT Score (ASPECTS) on emergency imaging was 7 (IQR 5–8). Of the 28 patients presented with tandem occlusion stroke, most commonly affecting the M1 segments (13/23) and M2 segments (12/23) of the middle cerebral artery (MCA), and the terminal ICA (5/23) (Fig. 1). Three patients also had a second intracranial occlusion in the M2, M3, or anterior cerebral artery (Table 1). Of the 33 patients, 28 (85%) underwent MT of the intracranial occlusion prior to stenting of the extracranial ICA with the CGuard stent. In 5 patients (15%), only stenting of the cervical ICA was performed, IVT was performed in 13 (39%) patients, 11 underwent subsequent MT of an intracranial occlusion and 1 received IVT without MT (drip-and-

ship patient with spontaneous recanalization of intracranial occlusion). One patient received intra-arterial urokinase along with MT as a rescue therapy.

**Intervention**

The underlying etiology of the ICA occlusion or stenosis was atherosclerosis in 29 (88%), ICA dissection in 3 patients (6%), and unclear in 1 patient (3%). Median time from symptom onset to recanalization was 371 min (IQR 270–510 min). Final intracranial recanalization success was mTICI2b in 11/28 patients (39%) and mTICI3 in 17/28 patients (61%). After deployment, 82% of stents were dilated with PTA and good recanalization was achieved in all
patients. All but one patient received a peri-interventional dose of 250–500 mg aspirin (one patient had a procedural intracranial hemorrhage determined by flat panel CT). One day after the intervention, DAPT with aspirin and clopidogrel was initiated in 25 patients, while 5 remained on aspirin monotherapy. Due to death shortly after the intervention, three patients received no therapy. Interventional characteristics are summarized in Table 2.

### Procedural Complications

Acute in-stent thrombus formation occurred in three patients (9%, 3/33). After PTA and aspiration (n = 1), aspiration alone (n = 1) or no rescue maneuver (due to only minor and peripheral thrombus, n = 1), all stents were patent at the end of the intervention. Glycoprotein IIb/IIIa inhibitors or heparin were not administered in these cases. Iatrogenic arterial dissection occurred in four patients (12%), only one dissection occurred after CAS with CGuard, three occurred while gaining intracranial access for mechanical thrombectomy by advancing the guide/intermediate catheter through due to tortuous vessel anatomy. After stenting with the CGuard, there was a suspected small dissection in one case at the distal end of the stent without hemodynamic relevance, and further treatment was not deemed necessary. Of the other three cases, two involved the cervical part of the ICA and which required additional stenting and extension of the lesion to the supraophthalmic segment without hemodynamic relevance occurred in one patient. In three of them, only the cervical part of the ICA was involved and extension of the lesion to the supraophthalmic segment occurred in one patient. Two dissections were flow-limiting and required additional stenting. Distal embolisms were found in the infarct territory on final control DSA after stenting in two patients (6%) and new clinically asymptomatic infarcts in new territory in follow-up imaging in two other patients (6%).

### Clinical Follow-up

Median NIHSS at discharge was 7 (IQR 2–15). All patients with available early follow-up imaging (CT, MRI or ultrasound) showed patent stents (31/33; 1 patient died due to sICH and 1 patient was transferred to another hospital before follow-up examination). A sICH occurred in one patient (3%) and asymptomatic intracranial hemorrhage (asICH) in nine patients (27%). Of the nine patients with aICH, seven were due to hemorrhagic transformation (five patients with hemorrhagic infarction (HI) 1, one with HI2 and two with parenchymal hematoma (PH) 2) and two due to SAH. Median duration of follow-up after the procedure was 90 days (IQR 89–98). Postinterventional stent occlusion occurred in one patient after 49 days, 1 patient suffered a transient ischemic attack (3%) and 12 patients (36%) had a follow-up mRS ≤ 2 at 3 months. Patients with unfavorable outcome (defined as 3-month mRS > 2) presented with significantly higher age (79 vs. 66 years, \( p = 0.044 \)) and a tendency towards lower ASPECTS score (7 vs. 8, \( p = 0.149 \)). The median NIHSS at 3 months in all survivors was 1 (IQR 0–4). The mortality rate at 3 months was 24% (8 patients). All follow-up characteristics are shown in Table 3.

### Discussion

The main findings of our study are: 1) The rate of acute in-stent thrombosis of the CGuard stent using a single antiplatelet protocol with aspirin is low in the acute stroke setting, 2) the use of the CGuard stent in the acute setting results in high patency rates at follow-up, and 3) periproce-
dural and postprocedural thromboembolic events after deployment of the CGuard stent are rare.

The finding that single-layer closed-cell stents were associated with lower rates of thromboembolic events in patients undergoing CAS compared to open-cell stents led to the introduction of double-layer carotid artery stents. The main objective was to prevent dislodgement of debris and subsequent embolization into the intracranial vessels while maintaining stent flexibility [21]. Their superior qualities have been confirmed by preliminary clinical studies [6, 22]; however, the clinical results from emergency settings remain conflicting as higher rates of in-stent thrombus formation were observed in braided metal double-layered stents with more thrombogenic material [8, 9]. Use of the CGuard stent, which has less thrombogenic material, has led to very low rates of postprocedural thrombotic events in elective settings; however, it was unclear whether these results can be translated to emergency ICA stenting.

**Acute and Delayed In-stent Thrombus Formation**

Dual antiplatelet therapy (DAPT) has been established as standard therapy for the prevention of in-stent thrombus formation [23]. Therapy duration ranges from 3 to 6 months and is a trade-off between in-stent thrombosis prevention and increased risk for sICH. Of our patients 25 (76%) received DAPT, the others either had a contraindication (e.g. hemorrhage on early follow-up imaging) or died before DAPT could be initiated.

The rate of acute in-stent thrombus formation in our cohort was 9%. This number is considerably lower than that reported by Bartolini et al. [9] (52.4%) or Pfaff et al. [24] (20.8%), who mainly examined the Casper-RX stent (MicroVention) in the acute setting. One explanation could be the different composition of the CGuard and the Casper-RX stent; the latter has a braided nitinol double-layer with potentially higher thrombogenicity. Yilmaz et al. [8], who examined a wider range of stents in acute tandem occlusion settings, also reported a much higher thrombosis rate (50%); however, our numbers are consistent with a study by Eker et al. who found a 9% [17] in-stent thrombosis rate in acute settings using both double-layer and single-layer stents for CAS in patients with tandem occlusions.

After adequate rescue therapy, all stents in our cohort were patent at the end of the intervention as well as at the 24–48 h follow-up examination. These results are even better than those generally reported for CAS in tandem occlusions. For example, in the TITAN study [25] the acute in-stent thrombosis rates during the intervention or within 24 h after the intervention were 4% and 15% in the antiplatelet pretreated and non-pretreated groups, respectively. Wallocha et al. [26] reported a 5% ICA re-occlusion rate at 24 h in a study using single-layer stents with postprocedural aspirin or DAPT. Another study on double-layered stents, CGuard and Roadsaver (Terumo, Shibuya, Japan), by de Vries et al. [21] observed postprocedural stent occlusions in five patients (9%). None of the affected patients was on antiplatelet therapy at time of presentation and 4/5 were treated with Roadsaver.

During the 3-month follow-up period, 1/17 patients (6%) had a delayed stent occlusion (after 49 days). This patient was asymptomatic and on standard DAPT. The stent occlusion was discovered incidentally during a routine ultrasound follow-up examination. In 7 patients, 3-month follow-up examination of stent patency was missing either due to imaging in other hospitals or due to postponed visits related to the COVID-19 pandemic. Our rate of delayed stent thrombosis is lower than in the study by Lamanna et al. [27] who evaluated deployment of the Casper-RX stent in the acute setting and reported 1/19 patients with delayed in-stent thrombosis (1 month after the intervention). In contrast, studies evaluating the CGuard stent in the elective setting found no re-occlusions after 30 days [22, 28] or even after 12 months [29]. CT or MRI at 3 months was unavailable in 9 patients, making it impossible to assess the occurrence of silent stroke in these patients.

**Other Procedure-related Complications and Clinical Outcome**

The rate of postinterventional symptomatic stroke in our cohort (0%) is in line with previous studies evaluating the CGuard in the elective setting. Whereas the PARADIGM study observed one event (1%) [30] IRON-GUARD [29] and the study by Wissgott et al. [22] reported no events; however, one patient (3%) had new neurologic symptoms (TIA after 97 days). sICH was observed in one patient who subsequently died, which is a lower rate than in other comparable studies [17, 27].

The 3-month mortality rate was 24%, comparable to another multicenter study assessing acute stenting in tandem occlusion with various stents (24%) [17] but higher than studies evaluating the Casper-RX stent (10% [27] and 14.3% [9], respectively) or in the TITAN study (11% and 19%) [25]. Patients with poor outcome were more likely to be older. There was also a non-significant tendency towards lower ASPECTS score on admission. Other baseline or procedural characteristics did not result statistically significant.

**Clinical Implications**

Deployment of the CGuard stent in the acute setting was technically feasible and successful in all patients, despite its relative stiffness when compared to other double-layered stents [22]. Furthermore, the low rate of acute and delayed
in-stent thrombus formation and of other procedure-related complications (e.g., distal emboli with new infarcts) as well as the low rate of occlusion of the stent in the follow-up period supported the effectiveness and safety of using the CGuard stent in the acute setting.

Strengths and Limitations

To our knowledge, this is the first study analyzing the use of the CGuard double-layered stent in emergency interventions.

The limitations of this study are: (1) its nonrandomized, single-center design, in which patients were prospectively entered into the Swiss Stroke Registry and then retrospectively analyzed, (2) the non-consecutive inclusion of patients, (3) the relatively small number of treated patients, which could have led to bias and lower generalizability of the results, (4) the absence of a matched comparison group, (5) a relatively large number of patients who were lost to follow-up due to examinations in other hospitals, and (6) non-standardized antiplatelet regimen after the intervention and the making of therapy decisions on an individual basis. Ideally, randomized controlled studies would be needed for confirmation of our results, or as alternatives, cohort-studies with matched controls or the inclusion of patients into multi-centric quality assurance registries.

Conclusions

The CGuard use in emergencies was technically feasible, the safety has to be confirmed by further multicentric studies.

Acknowledgements We thank Susan Kaplan for editorial assistance.

Author Contribution TK: author of the manuscript, data collection, statistical evaluation, image editing, CK: author of the manuscript, correction of the manuscript, statistical evaluation. JK: statistical evaluation, clinical evaluation. AM: correction of the manuscript, statistical evaluation. EIP: correction of the manuscript, data collection, clinical evaluation, involved in the treatment. TD: correction of the manuscript, data collection, clinical evaluation, involved in the treatment. SPP: involved in the treatment. AS: correction of the manuscript, clinical evaluation. MrH: correction of the manuscript, clinical evaluation. JG: study concept, involved in the treatment. PM: senior author, study concept, involved in the treatment, correction of the manuscript.

Funding Open access funding provided by University of Bern

Declarations

Conflict of interest J. Kaesmacher reports grants from the Swiss Academy of Medical Sciences/Bangerter Foundation, Swiss Stroke Society, and Clinical Trials Unit Bern during the conduct of the study. A. Scutelnic reports research support from Swiss Heart Foundation, not related to this manuscript. M.R. Heldner reports grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the SITEM Support Funds and from the Bangerter Foundation, and Advisory Board participation for Amgen, unrelated to the submitted work. J. Gralla is the global co-principal investigator of the SWIFT DIRECT trial (Solitaire With the Intention for Thrombectomy Plus Intravenous tPA Versus DIRECT Solitaire Stent-Retriever Thrombectomy in Acute Anterior Circulation Stroke; Medtronic), therefore consultant Medtronic. He receives Swiss National Foundation grants for magnetic resonance imaging in stroke. P. Mordasini reports research support from Siemens, Cerenovus, iSchemaview, Medtronic and Stryker, and receipt of honoraria and consultation fees from Medtronic, Cerenovus, Phenox and Microvention paid to the institution. T. Klafl, C. Kurmann, A. Mujanovic, E.I. Piechowiak, T. Dobrocky, S. Pilgram-Pastor and A. Scutelnic declare that they have no competing interests.

Ethical standards The study was approved by the local ethics committee (Kantonale Ethikkommission für die Forschung Bern, Bern Switzerland, amendment access number: 231/2014).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. International Carotid Stenting Study investigators; Ederle J, Dobson J, Featherstone RL, Bonati LH, van der Worp HB, de Borst GJ, Lo TH, Gaines P, Dorman PJ, Macdonald S, Lyer PA, Hendriks JM, Collum C, Nederkoorn PJ, Brown MM. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet. 2010;375:95–97. (Erratum in: Lancet. 2010;376:90).
2. Morris S, Patel NV, Dobson J, Featherstone RL, Richards T, Luengo-Fernandez R, Rothwell PM, Brown MM; International Carotid Stenting Study investigators. Cost-utility analysis of stenting versus endarterectomy in the International Carotid Stenting Study. Int J Stroke. 2016;11:446–53.
3. Zevulovs CB, Faroqui M, Quispe-Orozco D, Mendez-Ruiz A, Dajles A, Garg A, Galecio-Castillo M, Patterson M, Zaidat O, Ortega-Gutierrez S. Acute Carotid Artery Stenting versus Balloon Angioplasty for Tandem Occlusions: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2022;11:e022335.
4. de Donato G, Setacci F, Sirignano P, Galzerano G, Cappelli A, Setacci C. Optical coherence tomography after carotid stenting: rate of stent malapposition, plaque prolapse and fibrous cap rupture according to stent design. Eur J Vasc Endovasc Surg. 2013;45:579–87.
5. Yamada K, Yoshimura S, Miura M, Kanamaru T, Shindo S, Uchida K, Shirakawa M, Shibuya M, Imanaka T, Ishihara M, Masuyama T, Ishikura R, Kawasaki M. Potential of New-Generation Double-Layer Micromesh Stent for Carotid Artery Stenting in Patients with Unstable Plaque: A Preliminary Result Using OFDI Analysis. World Neurosurg. 2017;105:321–6.
6. Schofer J, Musialek P, Bijuklic K, Kolvenbach R, Trystula M, Sti-
dak Z, Sievert H. A Prospective, Multicenter Study of a Novel
Mesh-Covered Carotid Stent: The CGuard CARENET Trial
(Carotid Embolic Protection Using MicroNet). JACC Cardiovasc
Interv. 2015;8:1229–34.
7. Capoccia L, Sirignano P, Mansour W, d’Adamo A, Sbarigia E, Mar-
iani P, Di Biasi C, Speziale F. Peri-procedural brain lesions preven-
ciation in CAS (3PCAS): Randomized trial comparing CGuard™ stent
vs. Wallstent™. Int J Cardiol. 2019;279:148–53.
8. Yilmaz U, Körner H, Mühl-Bemningerhaus R, Simgen A, Kraus C,
Walter S, Behnke S, Säßbinder K, Reith W, Unger MM. Acute Oc-
cclusions of Dual-Layer Carotid Stents After Endovascular Emer-
tre emergency Tandem Lesions. Stroke. 2017;48:2171–5.
9. Bartolini B, Puccinelli F, Mosimann PJ, Hajdu SD, Vennac L,
Michel P, Salio G. Evaluating the effectiveness and safety of the
carotid Casper-RX stent for tandem lesions in acute ischemic
stroke. J Neurointerv Surg. 2019;11:772–4.
10. Texakalidis P, Giannopoulos S, Kokkinidis DG, Lanzino G. Ef-
effect of Open- vs Closed-Cell Stent Design on Periprocedural Out-
comes and Restenosis After Carotid Artery Stenting: A Systematic
Review and Comprehensive Meta-analysis. J Endovasc Ther.
2018;25:523–33.
11. Faateh M, Dakour-Aridi H, Mathlouthi A, Locham S, Naazie I,
Malas M. Comparison of open- and closed-cell stent design out-
comes after carotid artery stenting in the Vascular Quality Initiative.
J Vasc Surg. 2021;73:1639–48.
12. Abdullayev N, Maas V, Mtrotsaris A, Henning TD, Goertz L,
Borggrefe J, Chang DH, Onur OA, Liebig T, Schlamm T, Kab-
basch C. Comparative analysis of CGUARD embolic prevention
stent with Casper-RX and Wallstent for the treatment of carotid
artery stenosis. J Clin Neurosci. 2020;75:117–21.
13. Casana R, Tolva V, Odero A Jr, Malloggi C, Paolucci A, Triulzi F,
Silani V. Safety and Efficacy of the New Micromesh-Covered Stent
CGuard in Patients Undergoing Carotid Artery Stenting: Early Experience
From a Single Centre. Eur J Vasc Endovasc Surg. 2017;54:681–7.
14. Jung S, Mattle H, Horvath T, Seifighe D, Heldner M, Meinel T,
Bühlmann M, Prange U, Salmen S, Humm A, Renaud S, Bühler R,
Gralla J, Schroth G, Mordasini P, El-Koussy M, Angelillo-Scher-
rer A, Z’Graggen W, Bassetti C, Raabe A, Fischer U, Arnold M;
Stroke-Team Bern. Stroke guidelines of the Bern Stroke Network,
15. Guidelines. EuroIntervention. 2015;2016:12:e658–70.
16. Marnat G, Bühlmann M, Eker OF, Gralla J, Machi P, Fischer U,
Riquelme C, Arnold M, Bonafé A, Jung S, Costalat V, Mordasini P.
Multicentric experience in Distal-to-Proximal Revascularization of
Tandem Occlusion Stroke Related to Internal Carotid Artery Dis-
section. AJNR Am J Neuroradiol. 2018;39:1093–9.
17. Eker OF, Bühlmann M, Dargazanli K, Kaesmacher J, Mourand I,
Gralla J, Arquizon C, Fischer UM, Gascou G, Heldner M, Arnold M,
Costalat V, Mordasini P. Endovascular Treatment of Atheroscle-
rotic Tandem Occlusions in Anterior Circulation Stroke: Technical
Aspects and Complications Compared to Isolated Intracranial Oc-
cclusions. Front Neurol. 2018;9:1046.
18. Lockau H, Liebig T, Henning T, Neuschmelting V, Stetefeld H,
Kabbasch C, Dorn F. Mechanical thrombectomy in tandem occlu-
SION: procedural considerations and clinical results. Neuroradiol-
ogy. 2015;57:589–98.
19. Hacke W, Kaste M, Frieschi C, von Kummer R, Davalos A, Meier D,
Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Teje-
dor E, Trouillas P. Randomised double-blind placebo-controlled
trial of thrombolytic therapy with intravenous alteplase in acute is-
chaemic stroke (ECASS II). Second European-Australasian Acute
Stroke Study Investigators. Lancet. 1998;352:1245–51.
20. TIP Foundation for Statistical Computing. R: a language and envi-
norment for statistical computing. Vienna, Austria. 2019.
21. de Vries EE, Vonken EJ, Kappelle LJ, Toorop RJ, de Borst GJ.
Short-Term Double Layer Mesh Stent Patency for Emergent or
Elective Carotid Artery Stenting. Stroke. 2019;50:1898–901.
22. Wisscott G, Schmidt W, Brandt-Wunderlich C, Behrens P, An-
dresen R. Clinical Results and Mechanical Properties of the Carotid
CGUARD Double-Layered Embolic Prevention Stent. J Endovasc
Ther. 2017;24:130–7.
23. Jeger RV, Pflisterer ME, Strensen R, von Felten S, Alber H,
Bonetti PO, Eberl F, Erne P, Pedrazzini G, Rickli H, Galatius S,
Kaiser CA; BASKET and BASKET-PROVE investigators. Trade-
off between bleeding and stent thrombosis in different dual an-
tiplatelet therapy regimes: Importance of case fatality rates and
effective treatment durations. Am Heart J. 2014;168:698–705.
24. Pfaff JAR, Maurer C, Broussalis E, Janssen H, Blanc R, Dargazan-
li C, Costalat V, Piotin M, Runck F, Berlis A, Killer-Oberpfalzer M,
Hensler JT, Bendszus M, Wodarg F, Möhlenbruch MA. Acute
thromboses and occlusions of dual layer carotid stents in en-
dovascular treatment of tandem occlusions. J Neurointerv Surg.
2020;12:33–7.
25. Zhu F, Anadani M, Labreuche J, Spiootta A, Turjman F, Piotin M,
Steglich-Armholm H, Holmman Päätöser M, Taschner C, Eiden S,
Haussen DC, Nogueira RG, Papanagiotou P, Bouchakova M, Sid-
diqui AH, Lapergue B, Dorn F, Cognard C, Killer-Oberpfalzer M,
Mangiafico S, Ribo M, Psychogios MN, Labeyrie MA, Mazighi M,
Biondi A, Anzianonn R, Bracard S, Richard S, Gory B; TITAN
Investigators. Impact of Antiplatelet Therapy During Endovascular
Therapy for Tandem Occlusions: A Collaborative Pooled Analysis.
Stroke. 2020;51:1522–9.
26. Wallocha M, Chapot R, Nordmeyer H, Fiehler J, Weber R,
Stracke CP. Treatment Methods and Early Neurologic Improve-
ment After Endovascular Treatment of Tandem Occlusions in
Acute Ischemic Stroke. Front Neurol. 2019;10:127.
27. Lamanna A, Maingard J, Kok HK, Barras C, Jabbi A, Thijis V,
Chandra R, Brooks DM, Asadí H. Carotid Artery Stenting in Acute
Stroke Using a Microporous Stent Device: A Single-Center Expe-
rience. World Neurosurg. 2019;127:e1003–12.
28. Tsigkopoulos K, Papoutis I, Abatzis-Papadopoulos M, Kousidis P,
Mpsimpos D, Melas N, Stavridis K, Karamanos D, Lazaridis I,
Sarazis N. Thirty-Day Results of the Novel CGuard-Covered Stent
in Patients Undergoing Carotid Artery Stenting. J Endovasc Ther.
2021;28:542–8.
29. Capoccia L, Sirignano P, Mansour W, Sbarigia E, Speziale F.
Twelve-month results of the Italian registry on protected CAS with
the mesh-covered CGuard stent: the IRON-Cguard study. Euro-
Intervention. 2018;14:1150–2.